Emma C Tallantyre
Overview
Explore the profile of Emma C Tallantyre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
548
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
12.
Allen-Philbey K, De Trane S, Mao Z, Alvarez-Gonzalez C, Mathews J, MacDougall A, et al.
Ther Adv Neurol Disord
. 2022 Feb;
14:17562864211057661.
PMID: 35173808
Objective: To report on safety and effectiveness of subcutaneous cladribine (Litak) in multiple sclerosis (MS) patients. Methods: Litak was offered to MS-patients irrespective of disease course. Litak 10 mg was...
13.
Wood C, Robertson N, Htet Z, Tallantyre E
Mult Scler Relat Disord
. 2022 Jan;
58:103492.
PMID: 35066268
Background: Dimethyl fumarate (DMF) is a disease modifying therapy (DMT) used in the management of Multiple Sclerosis (MS). Lymphopenia occurs in approximately 30% of people receiving this medication. The recently...
14.
Tallantyre E, Vickaryous N, Anderson V, Asardag A, Baker D, Bestwick J, et al.
Ann Neurol
. 2021 Oct;
91(1):89-100.
PMID: 34687063
Objective: The purpose of this study was to investigate the effect of disease modifying therapies on immune response to severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines in people with multiple...
15.
Garjani A, Hunter R, Law G, Middleton R, Tuite-Dalton K, Dobson R, et al.
Mult Scler
. 2021 Jun;
28(7):1060-1071.
PMID: 34080892
Background: People with MS (pwMS) have had higher rates of anxiety and depression than the general population before the COVID-19 pandemic, placing them at higher risk of experiencing poor psychological...
16.
Garjani A, Middleton R, Hunter R, Tuite-Dalton K, Coles A, Dobson R, et al.
Mult Scler Relat Disord
. 2021 May;
52:102939.
PMID: 34010764
Background: Infections can trigger exacerbations of multiple sclerosis (MS). The effects of the coronavirus disease 2019 (COVID-19) on MS are not known. The aim of this study was to understand...
17.
MacIver C, Ebden S, Tallantyre E
Pract Neurol
. 2021 May;
21(3):216-224.
PMID: 33963086
MRI is a staple of the neurologist's armoury when facing diagnostic challenges. At times, it can reveal or confirm the diagnosis with clarity, at others it brings us no further...
18.
Winter M, Tallantyre E, Brice T, Robertson N, Jones D, Chamberland M
Brain Commun
. 2021 May;
3(2):fcab065.
PMID: 33959710
Cognitive difficulties are common and a key concern for people with multiple sclerosis. Advancing knowledge of the role of white matter pathology in multiple sclerosis-related cognitive impairment is essential as...
19.
Tallantyre E, Evans N, Parry-Jones J, Morgan M, Jones C, Ingram W
J Neurol
. 2020 Nov;
268(4):1544-1554.
PMID: 33140239
Chimeric antigen receptor (CAR)-expressing T cells now offer an effective treatment option for people with previously refractory B cell malignancies and are under development for a wide range of other...
20.
Anderson V, Bentley E, Loveless S, Bianchi L, Harding K, Wynford-Thomas R, et al.
J Neurol Sci
. 2020 Aug;
417:117079.
PMID: 32781395
Background: Prognostication in multiple sclerosis (MS) remains challenging. Biomarkers capable of providing this information at diagnosis would be valuable in shaping therapeutic decisions. Measurement of neurofilament light (NfL) has shown...